The association between plasma tryptophan catabolites and depression
| Autor: | Yuri Milaneschi, Brenda W.J.H. Penninx, Robert A. Schoevers, Heiko G. Niessen, Kelly A. Allers, Erik J. Giltay, Sigurd D. Süssmuth, Aartjan T.F. Beekman, Sascha Keller |
|---|---|
| Přispěvatelé: | Psychiatry, Amsterdam Neuroscience - Complex Trait Genetics, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, APH - Mental Health, APH - Digital Health, Clinical Cognitive Neuropsychiatry Research Program (CCNP), Interdisciplinary Centre Psychopathology and Emotion regulation (ICPE) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Kynurenine pathway Immunology INVENTORY METABOLISM Kynurenic Acid Tryptophan catabolites Gastroenterology Behavioral Neuroscience chemistry.chemical_compound Kynurenic acid Internal medicine medicine ANXIETY Humans Depression (differential diagnoses) Kynurenine Inflammation Depressive Disorder Major HIPPOCAMPAL Endocrine and Autonomic Systems business.industry Depression ALPHA-INDUCED CHANGES INDUCTION Tryptophan GAMMA medicine.disease Pathophysiology chemistry Major depressive disorder Anxiety medicine.symptom business MEDIATE Symptom profiles Quinolinic acid |
| Zdroj: | Brain, Behavior, and Immunity, 97, 167-175. Academic Press Inc. Milaneschi, Y, Allers, K A, Beekman, A T F, Giltay, E J, Keller, S, Schoevers, R A, Süssmuth, S D, Niessen, H G & Penninx, B W J H 2021, ' The association between plasma tryptophan catabolites and depression: The role of symptom profiles and inflammation ', Brain, Behavior, and Immunity, vol. 97, pp. 167-175 . https://doi.org/10.1016/j.bbi.2021.07.007 Brain, Behavior, and Immunity, 97, 167-175. ACADEMIC PRESS INC ELSEVIER SCIENCE Brain behavior and immunity, 97, 167-175. ACADEMIC PRESS INC ELSEVIER SCIENCE |
| ISSN: | 0889-1591 |
| Popis: | Background: Tryptophan catabolites ("TRYCATs") produced by the kynurenine pathway (KP) may play a role in depression pathophysiology. Studies comparing TRYCATs levels in depressed subjects and controls provided mixed findings. We examined the association of TRYCATs levels with 1) the presence of Major Depressive Disorder (MDD), 2) depressive symptom profiles and 3) inflammatory markers.Methods: The sample from the Netherlands Study of Depression and Anxiety included participants with current (n = 1100) or remitted (n = 753) MDD DSM-IV diagnosis and healthy controls (n = 642). Plasma levels of tryptophan (TRP), kynurenine (KYN), kynurenic acid (KynA), quinolinic acid (QA), C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor (TNF) were measured. Atypical/energy-related symptom (AES), melancholic symptom (MS) and anxious-distress symptom (ADS) profiles were derived from questionnaires.Results: After adjustment for age, sex, education, smoking status, alcohol consumption and chronic diseases, no significant differences in TRYCATs were found comparing MDD cases versus controls. The MS profile was associated (q < 0.05) with lower KynA (beta = -0.05), while AES was associated with higher KYN (beta = 0.05), QA (beta = 0.06) and TRP (beta = 0.06). Inflammatory markers were associated with higher KYN (CRP beta = 0.12, IL-6 beta = 0.08, TNF beta = 0.10) and QA (CRP beta = 0.21, IL-6 beta = 0.12, TNF beta = 0.18). Significant differences against controls emerged after selecting MDD cases with high (top 30%) CRP (KYN d = 0.20, QA d = 0.33) and high TNF (KYN d = 0.24; QA d = 0.39).Conclusions: TRYCATs levels were related to specific clinical and biological features, such as atypical symptoms or a proinflammatory status. Modulation of KP may potentially benefit a specific subset of depressed patients. Clinical studies should focus on patients with clear evidence of KP dysregulations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect